FOLFOX + bevacizumab + vitamin D

FOLFOX + bevacizumab + vitamin D is a combination regimen used primarily in the treatment of colorectal cancer. It consists of three main components: - **FOLFOX** is a chemotherapy regimen that includes folinic acid (leucovorin), fluorouracil (5-FU), and oxaliplatin. These agents work synergistically to inhibit DNA synthesis and cell division, targeting rapidly dividing cancer cells[1][2][4]. - **Bevacizumab** is a monoclonal antibody that inhibits vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis, which restricts the tumor's blood supply. - **Vitamin D** is included as a dietary supplement; it may have adjunctive roles in modulating immune response or supporting bone health but does not have direct antineoplastic activity. This combination leverages cytotoxic chemotherapy, antiangiogenic targeted therapy, and nutritional supplementation to improve outcomes in advanced or metastatic colorectal cancer. The addition of bevacizumab to FOLFOX has been shown to enhance efficacy by further inhibiting tumor growth through antiangiogenic mechanisms. Vitamin D supplementation may be considered for its potential supportive benefits but is not an established anticancer agent.